First clinical study started with BAN2401
BAN2401 is a novel antibody targeting the neurotoxin believed to cause Alzheimer s disease and developed by BioArctic Neuroscience.
News
FDA approves clinical study in Alzheimer patients
Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease.
...
BioArctic receives milestone
BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment ...
Patents on Alzheimer model granted
BioArctic´s patents on an Alzheimer transgenic model have been granted in the US and in Australia.
US vaccination patent approved
BioArctic s US patent on an Alzheimer vaccine was approved today. BioArctic Neuroscience AB has a proprietary technological platform for immunotherapy against misfolded proteins.
Alzheimer patent granted in Australia
The Australian patent office has granted a BioArctic patent for Prevention and Treatment of Alzheimer´s Disease.
BioArctic rewarded
Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord ...